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Abstract Neovascularization, an essential step for tumor pro-
gression and metastasis development, can be modulated by the
presence of macrophages (Mps) in the tumor microenvironment.
The ability of Mps to regulate the angiogenicity of the LMM3
tumor cell line was studied. Peritoneal Mps from LMM3 tu-
mor-bearing mice (TMps) potentiate in vivo LMM3 angiogenic-
ity. These results were con¢rmed by CD31 immunoblotting as-
says. The activity of TMps depended on nitric oxide synthase
(NOS) and arginase (A) activity. By immunoblotting we evi-
denced that AI and AII isoforms were up-regulated in TMps
while the inducible and neuronal NOS isoforms were highly
expressed in normal Mps. TMps might positively modulate tu-
mor growth by stimulating angiogenic cascade mainly through
polyamine synthesis.
, 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The role of nitric oxide (NO) in tumor biology has been
extensively studied. Several authors have evidenced that NO
plays a major role in angiogenesis and tumor progression
[1,2]. It is well established that angiogenesis is essential for
tumor and metastasis growth. LMM3 cells, derived from a
murine mammary adenocarcinoma, induce a strong angiogen-
ic response in vivo, that partially depends on arginine meta-
bolic products via nitric oxide synthase (NOS), as it dimin-
ishes by the addition of NOS inhibitors (Ng-nitro-L-arginine
methyl esther, L-NAME; and aminoguanidine, AG) [3].
Malignant tumors contain macrophages (Mps) as a major
component of the host leukocytic in¢ltrate and the role of
Mps in tumor progression have given o¡ contradictory evi-
dence [4]. It has been recognized that Mps can act either as
negative regulators by achieving tumor cytotoxicity, or as
positive regulators by promoting tumor growth. Both actions
can be exerted via L-arginine metabolism [5].
Here we investigate the modulatory role of peritoneal Mps
from LMM3 tumor-bearing mice (TMps) on the angiogenic
response induced by LMM3 cells in relation to arginine me-
tabolism through NOS/arginase (A) pathway.
2. Materials and methods
2.1. Animals and tumor cell line
BALB/c mice (females, 12 weeks old) from our Animal Division
were used. Animal care was provided in accordance with that outlined
in the Guide for Care and Use of Laboratory Animals (NIH Publi-
cation, 1986). The tumor-cell line LMM3 was previously selected from
a spontaneous syngeneic mammary adenocarcinoma MM3 [6]. Cell
suspensions with more than 90% viability (assessed by trypan blue)
were used. Tumor-bearing mice (TBM) were obtained by s.c. inocu-
lation of 4U105 LMM3 cells into the £ank.
2.2. Puri¢cation of peritoneal macrophages
Peritoneal cells from normal and TBM (7 days post inoculation,
with similar palpable tumors) were obtained by washing the peritoneal
cavity with 5 ml MEM supplemented with 10% FCS. The adherent
Mps from normal (NMps) and TMps were puri¢ed by adhesion to
plastic for 2 h. After washing twice with PBS, adherent cells were
scraped and resuspended in culture medium. Cell viability (s 95%)
was assessed by trypan blue exclusion test.
2.3. Tumor-induced angiogenesis
2.3.1. Bioassay. Tumor-induced angiogenesis was quanti¢ed using
an in vivo bioassay previously described [7]. Brie£y, 2U105 LMM3
cells were inoculated i.d. alone or with NMps or TMps (2U103) in
both £anks of female normal mice (n=4 for each group). In another
set of experiments, previous to the inoculation, Mps were treated
during 2 h with: 2U1033 M L-NAME, 1033 M aminoguanidine
(AG), 5U1032 M valine (Val) or 1034 M Ng-hydroxy-L-arginine
(NOHA). On day 5, animals were killed with ether. The inoculated
sites were photographed and the slides were projected onto a reticular
screen to count the number of vessels/mm2 skin.
2.3.2. Detection of CD31 (PECAM-1) by Western blot. Skin
strips from the angiogenic site devoided of hair, were obtained. Tis-
sues were homogenized at 4‡C in four volumes of 20 mM Tris^HCl,
10 mM EGTA, 10 mM EDTA, 1 mM phenylmethylsulfonyl £uoride
(PMSF), 1 mM dithiothreitol, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin,
10 Wg/ml soybean trypsin inhibitor, pH 7.4. Homogenates were cen-
trifuged at 4‡C, 10 000 rpm for 10 min. Supernatants were stored at
380‡C until use and protein concentration was determined by the
method of Lowry [8]. Samples were subjected to 10% sodium dode-
cylsulfate^polyacrylamide gel electrophoresis (SDS^PAGE). After
electrophoresis, proteins were electrotransferred to nitrocellulose
membranes and washed. The nitrocellulose strips were blocked in 20
mM Tris^HCl bu¡er, 500 mM NaCl, 0.05% Tween 20 (TBST) with
5% skimmed milk for 1 h at room temperature and subsequently
incubated overnight with a goat polyclonal antibody anti-PECAM-1
(Santa Cruz Biotechnology). After several rinses, membranes were
incubated 1 h with alkaline phosphatase-conjugated secondary anti-
body anti-goat IgG. The proteins were visualized using a mixture of
nitroblue tetrazolium chloride (NBT)/5-bromo-4-chloro-3-indolyl
phosphate-p-toluidine salt (BCIP). Quanti¢cation was performed us-
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ing a computerized densitometer connected to an image analyzer (Bio-
Rad GS 700).
2.4. Determination of nitric oxide
Levels of NO released into the cell culture media by NMps or
TMps were determined by Griess reaction [9]. Brie£y, 105 cells were
incubated in triplicate in 96-well plates in 200 Wl MEM alone or with
the inhibitors mentioned above. After 2 h incubation, medium was
replaced by fresh MEM. After 24 h, 100 Wl of the supernatants were
added to an equal volume of Griess reagent (1% sulphanyl amine in
30% acetic acid with 0.1% N-1-naphtyl ethylenediamine dihydrochlor-
ide in 60% acetic acid). Absorbance was measured at 540 nm with an
ELISA Reader (Labsystem). Results are expressed in micromolar per
million cells (WM/106 cells).
2.5. Detection of NOS isoforms by Western blot
Lysates were prepared by resuspending the cells (2U107 Mps) in
1 ml of lysis bu¡er containing 50 mM Tris^HCl (pH:8), 100 mM
NaCl, 2 mM EGTA, 2 mM EDTA, 1% Triton X-100, 10 mM
PMSF, 20 Wg/ml aprotinin, 20 Wg/ml leupeptin, 100 Wg/ml soybean
trypsin inhibitor. Cell lysates were centrifuged at 10 000Ug for 10
min. Protein concentration in supernatants was measured by the
method of Lowry [8]. Samples were subjected to 7.5% SDS^PAGE
electrophoresis, seeding 20^50 Wg protein in each lane. Proteins were
transferred to nitrocellulose membranes and incubated overnight with
a rabbit polyclonal antibody anti-nNOS or anti-eNOS and a goat
polyclonal antibody anti-iNOS (Santa Cruz Biotechnology). After
several rinses strips were incubated at 37‡C during 1 h with alkaline
phosphatase-conjugated secondary antibody (rabbit anti-IgG or goat
anti-IgG, respectively). Bands were visualized with NBT/BCIP and
quanti¢ed by densitometry [10].
2.6. Arginase activity assay
Arginase (A) activity was determined in cell lysates according to
previously described methods [11]. Brie£y, 105 cells treated or not
with 1034 M L-NMMA, 1033 M AG, 5U1032 M Val or 1034 M
NOHA were lysed with 0.5 ml 0.1% Triton X-100, 25 mM Tris^HCl
containing 5 mM MnCl2, pH 7.4. The enzyme was activated at 56‡C
and 25 Wl of the activated lysate were incubated with 25 Wl of 0.5 M
arginine, pH 9.7, at 37‡C for 60 min. The reaction was stopped in acid
medium. Urea concentration was measured at 540 nm with a micro-
plate reader. Results are expressed as Wmol of urea per hour per 106
cells (Wmol/h/106 cells).
2.7. Detection of arginase isoforms by Western blot
Adherent cells were rinsed twice with ice-cold PBS and then scraped
into 300 Wl lysis bu¡er: 50 mM Tris^HCl (pH 7.5), 0.1 mM EDTA,
0.1 mM EGTA, 1 Wg/ml leupeptin, 1 Wg/ml aprotinin and 0.1 mM
PMSF. Lysis was completed by sonication. Samples (25 Wg) were
subjected to 10% SDS^PAGE as it was stated in previous methods
[12]. Nitrocellulose membranes were incubated overnight with a
monoclonal anti-mouse arginase I antibody (BD Transduction Labo-
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Fig. 1. A: LMM3 tumor cells (2U105) were injected alone (b) or
with NMps (2U103, c) or TMps (2U103, d) as stated in Section 2.
Angiogenic response was measured as number of vessels per square
millimeter (N). *P6 0.0001 vs. N of normal skin (a) 1.65R 0.20 ac-
cording to Kruskal^Wallis test. B: Western blot for CD31 expres-
sion in angiogenic skin. Protein molecular weight is indicated on the
left. Control corresponds to normal skin. Lower panel shows densi-
tometric analysis of the bands expressed as optical density units
(OD)/mm2.
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Fig. 2. LMM3 tumor cells alone or co-injected with TMps in the
optimal relation tested, treated or not with NOS inhibitors (2U
1033 M L-NAME, 1033 M AG) or arginase inhibitors (5U1032 M
Val or 1034 M NOHA) during 2 h and inoculated to syngeneic re-
cipients as was stated in Section 2. Each value represents the
meanRS.D. of four experiments. *P6 0.001 and **P6 0.0001.
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ratories) or with a rabbit anti-arginase II antibody (kindly gifted by
Dr. Masataka Mori) [13,14]. The secondary antibody conjugated with
alkaline phosphatase-anti-mouse or anti-rabbit IgG was added for 1 h
at 37‡C. Proteins were visualized using a mixture of NBT/BCIP and
quanti¢ed by a densitometric analysis.
2.8. Drugs
All drugs were purchased from Sigma-Aldrich unless otherwise
stated. Solutions were prepared fresh daily.
3. Results
3.1. Angiogenic activity of peritoneal Mps
Since LMM3 cells are strongly angiogenic, here we explored
the ability of Mps to modulate the neovascular response. Peri-
toneal TMps (2U105) alone, elicited a positive angiogenic
response (2.7 R 0.14 vessels/mm2) comparable to LMM3 cells
(2.91R 0.38). When TMps were co-injected with LMM3 cells
in a subthreshold dose (TMps:LMM3, 2U103 :2U105), that
was ine¡ective per se, they markedly potentiated tumor cell
angiogenesis (Fig. 1A). NMps were devoided of angiogenic
activity either alone (1.79 R 0.14) or in the presence of
LMM3 cells (Fig. 1A). These results were con¢rmed by study-
ing CD31 expression in angiogenic skin. As is shown in Fig.
1B, CD31 expression is negative in normal skin and becomes
evident in the LMM3 angiogenic site, increasing in the skin of
animals inoculated with LMM3 plus TMps. By immunohis-
tology we observed that anti-CD31 antibody only binds to
neovessels (data not shown).
3.2. Participation of Mps NOS and A in tumor angiogenesis
Since L-arginine metabolism via the NOS pathway was in-
volved in LMM3 cell angiogenesis [3], we investigated whether
Mps could be stimulating angiogenic activity by arginine ca-
tabolites. As shown in Fig. 2, the preincubation of TMps with
a non-selective inhibitor of NOS, L-NAME, or with AG
(iNOS inhibitor), signi¢cantly blocked their stimulatory ac-
tion on LMM3-induced angiogenic response. Furthermore,
when TMps were treated with Val or NOHA, that inhibit A
pathway, a greater reduction in the angiogenic response was
detected (nearly 50% inhibition), pointing to a main role of
NOS and A in TMp pro-angiogenic activity.
3.3. Expression of NOS and A isoenzymes in Mps
Studying NOS enzymes expression in NMps and TMps we
detected iNOS and nNOS isoforms in both Mps populations,
the former being more highly expressed than the latter. Endo-
thelial NOS protein was undetectable in both populations.
TMps exhibited lesser amounts of both isoenzymes in com-
parison to NMps (Fig. 3, lower panel). The decrement in
protein expression was accompanied by a fall in NOS activity
as it was con¢rmed by nitrite determination: TMps produced
signi¢cantly lower amounts of NO (30%) than NMps (Fig. 3,
upper panel).
Expression of A isoforms was also assayed by Western blot.
Both AI and AII were expressed in NMps and in TMps but,
contrary to NOS, both proteins were up-regulated in TMps
(Fig. 3, lower panel). The increment in protein expression
correlated with an increase by 100% in A activity, measured
as urea production, in TMps compared to NMps (Fig. 3,
upper panel).
3.4. Interactions between NOS and A in macrophages
According to our results, we investigated interactions be-
tween NOS and A pathways in NMps and TMps by measur-
ing their respective products, nitrite and urea, in the presence
of adequate inhibitors. As mentioned earlier, NMps were able
to liberate 44% more nitrite to the culture medium than TMps
(Fig. 3, upper panel). Both NOS inhibitors, L-NMMA and
AG, were equipotent to inhibit NO production in both Mp
populations (Fig. 4A). The ability of Val, which interferes
±
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±
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Fig. 3. Upper panel: NOS activity measured as NO32 (WM/10
6 cells) and arginase activity measured as urea (Wmol/h/106 cells) were determined,
in basal conditions, in the culture supernatants of NMps or TMps. Values are meanRS.E.M. of four experiments performed. Lower panel: im-
munoblotting assay for NOS and arginase (A). Left: iNOS (130 kDa) and nNOS (155 kDa) isoforms in NMps and TMps. Right: Western
blot assay to detect AI and AII isoforms. First lane: AI positive control. Bands were quanti¢ed by densitometric analysis. One representative
experiment of four performed.
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with A pathway, to potentiate NO synthesis was signi¢cantly
greater in TMps than in NMps, while NOHA potentiated NO
production only in NMps. As mentioned above, TMps pro-
duced signi¢cantly higher amounts of urea than NMps in
basal conditions. Val always inhibited urea production while
NOHA was more e¡ective in inhibiting A activity in TMps
than in NMps (Fig. 4B). It is also shown in Fig. 4B that the
addition of NOS inhibitors (L-NMMA or AG) induces urea
formation over basal levels only in NMps.
It must be mentioned that we could not detect cytotoxic
e¡ects of TMps against LMM3 cells at the e¡ector:target
ratio 1:100 used in the angiogenesis assays. However, cyto-
toxicity was exerted using target:e¡ector ratios 1:25 and 1:50
(data not shown).
4. Discussion
Mps perform a multitude of functions essential for tissue
remodeling, in£ammation and immunity by secreting cyto-
kines, growth factors and prostaglandins [15]. The majority
of malignant tumors contain Mps as a major component of
the host leukocytic in¢ltrate [4]. These tumor-associated Mps
are recruited into the tumor mass from the circulation by the
action of di¡erent chemotactic factors. Tumor-associated Mps
not only exert cytotoxicity without stimuli but, to the con-
trary, they can also exert pro-tumor functions [16]. Concord-
antly, we observed that TMps were able to exert pro-tumor
functions via a complex mechanism. We here demonstrated
that a su⁄cient number of TMps not only induce per se a
positive angiogenic response tested in vivo, but when co-in-
jected in a TMp/LMM3 ratio less than 1/10 strongly up-reg-
ulate LMM3 tumor cell-induced angiogenesis. It is notewor-
thy that this same low concentration of TMps or NMps alone
were ine¡ective to elicit angiogenesis ; however, 100-fold high-
er number of TMps but not NMps were angiogenic per se.
Akedo et al. [17] have reported that Mps had the potential to
induce the invasiveness of tumor cells in vitro and in vivo,
postulating that this e¡ect occurred depending on the ratio of
the number of Mps to that of tumor cells. Thus, Mps were
stimulatory to tumor cells when the ratio remained between
0.1 and 1.0, attributing the positive in£uence on tumor pro-
gression and metastasis to the production of oxidative metab-
olites by active Mps.
Mps use L-arginine to synthesize NO through NOS iso-
forms and/or urea to produce ornithine via arginases activa-
tion. It has been largely discussed whether arginine metabo-
lites act for or against tumor growth. It has been suggested
that L-arginine-dependent reactive nitrogen products hold a
major role in tumor cell killing by activated Mps [18]. iNOS
expression and activity has been linked with pathological sta-
tus as chronic in£ammation and tumors [19]. In our model the
stimulatory action of TMps on LMM3 angiogenesis was
blunted by selective inhibiting iNOS with AG or using L-
NAME as non-selective inhibitor. We cannot dismiss that
nNOS might be also involved in this process. Thus, although
TMps produce lower amounts of NO than NMps, with con-
comitantly lower expression of iNOS and nNOS proteins, it
seems that this low level of NO is enough to enhance tumor
angiogenesis.
Taking into account that L-arginine metabolism could be
derived to the A pathway, we also tested the action of A
inhibitors on TMps-stimulated tumor angiogenesis. We dem-
onstrate that both Val and NOHA, which signi¢cantly inhib-
ited urea formation, potently reduce stimulatory e¡ect of
TMps on LMM3-induced neovascularization. The synthesis
of polyamines via AI and AII isoforms is essential for human
tumor cell proliferation [20^22]. But other sources of poly-
amine precursors, such as those from Mps, can contribute
to tumor growth and might not be discarded. The fact that
NMps did not a¡ect angiogenesis although producing high
amounts of NO needs further studies.
It has been described that iNOS and arginases are co-ex-
pressed in murine Mps, resulting in complex interactions
where the level of substrate and/or product of one enzyme
may regulate the activity of the other enzyme [5]. By immu-
noblotting we evidenced the presence of iNOS, nNOS, AI and
AII in peritoneal Mps. But while both NOS isoforms actively
predominate in NMps, arginases are up-regulated in TMps.
The preincubation of TMps with high doses of Val or NOHA
strongly inhibited A activity, while only Val was e¡ective in
A
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Fig. 4. Untreated NMps and TMps (basal) or treated with 2U
1033 M L-NAME, 1033 M AG, or 5U1032 M Val or 1034 M
NOHA were used to determine: NOS activity measured as NO32
(WM/106 cells) into the culture supernatants (A) or arginase activity
measured as urea (Wmol/h/106 cells) production (B). Values are
meanRS.E.M. of four experiments performed in duplicate. *Signi¢-
cantly di¡erent from basal at P6 0.05.
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enhancing NO synthesis. These results could probably be due
to inhibitor selectivity for one or both A isoforms in these
cells. Further experiments are needed to clarify this mecha-
nism. On the contrary, the inhibition of A in NMps with Val
or NOHA signi¢cantly increases nitrite production while NOS
blockade stimulates urea production, pointing to a reciprocal
regulation between both enzymes. This cross-regulatory mech-
anism seems to be more evident in NMps, since they express
higher amounts of both active proteins.
Taken together, our results suggest that peritoneal Mps
from TBM, far from exerting tumoricidal activity when
present at low rates, contribute to enhance LMM3 angio-
genesis. By switching L-arginine from NOS to A metabolic
pathway, TMps diminish NO levels and probably provide
polyamine precursors to favor neovascularization and tumori-
genesis.
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